Search - tctmd.com

Displaying 741 - 760 of 952

Sort: Relevancy | Date

News Daily News

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

April 10, 2012

News Daily News

Baseline Anemia Raises Risk for Stent Thrombosis After DES

L.A. McKeown

April 04, 2012

News Daily News

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

April 03, 2012

News Daily News

PRODIGY Published: No Advantage to Long-term Clopidogrel

April 03, 2012

Presentation

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

Presenter: Marco Valgimigli

April 02, 2012

News Conference News ACC 2012

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Yael L. Maxwell

April 02, 2012

News Daily News

Rapid Bedside Genotyping May Help Guide Antiplatelet Strategy After PCI

Caitlin E. Cox

March 30, 2012

News Daily News

El Genotipado Rápido a Pie de Cama podría Determinar la Estrategia Antiplaquetaria tras una PCI

Caitlin E. Cox

March 30, 2012

News Industry News

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

March 27, 2012

News Conference News ACC 2012

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

L.A. McKeown

March 26, 2012

News Conference News ACC 2012

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

March 26, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Daily News

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Caitlin E. Cox

March 25, 2012

News Conference News ACC 2012

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

March 25, 2012

News Conference News ACC 2012

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

L.A. McKeown

March 25, 2012

Presentation ACC 2012

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Presenter: Myeong-Ki Hong

March 25, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

News Conference News ACC 2012

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

Jason Kahn

March 24, 2012

News Conference News ACC 2012

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

L.A. McKeown

March 24, 2012

News Conference News ACC 2012

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

March 24, 2012

Advertisement

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

Baseline Anemia Raises Risk for Stent Thrombosis After DES

Se Publica el PRODIGY: No se observa Ventaja alguna a Largo Plazo con el Clopidogrel

PRODIGY Published: No Advantage to Long-term Clopidogrel

Short- vs. Long-term Duration of Dual Antiplatelet Therapy (DAPT) After Coronary Stenting

ACC-i2 Scientific Session 2012: Cooperation Key as Practice Changing Results Released

Rapid Bedside Genotyping May Help Guide Antiplatelet Strategy After PCI

El Genotipado Rápido a Pie de Cama podría Determinar la Estrategia Antiplaquetaria tras una PCI

Data Presented at ACC.12 Demonstrate that OrbusNeich’s Genous™ Stent is Feasible and Safe in STEMI Patients

Two Studies Highlight Safety, Efficacy of Biodegradable Polymer SES

RESOLUTE: Zotarolimus-Eluting Stent Fares Well at 2 Years

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

Meta-Analysis: Cobalt-Chromium EES Cut Stent Thrombosis Compared with BMS, Other DES

EXOME: New Genetic Sequencing Zeroes in on Clopidogrel Response Variants

Adjunctive Cilostazol Noninferior to Double-Dose Clopidogrel in All-Comer PCI Trial

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Prasugrel Effective in Stable Patients With Poor Response to Clopidogrel

New Antiplatelet Agent Vorapaxar Shows Promise, But At the Expense of Bleeding

Anti-inflammatory Lowers In-Stent Late Loss After BMS Implantation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content